Mylotarg FDA Approval History
Mylotarg (gemtuzumab ozogamicin) is a D33-directed antibody-drug conjugate indicated for:
- treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older.
- treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older.
Development Timeline for Mylotarg
|Sep 1, 2017||FDA Approves Mylotarg (gemtuzumab ozogamicin) for the Treatment of Acute Myeloid Leukemia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.